Disclosed is a pharmaceutical composition for inhibiting infection and replication of influenza A and B virus, and the manufacture thereof. The pharmaceutical composition is produced by a manufacture of low-temperature disintegrating cyanobacteria, comprising the steps of: (a)mixing cyanobacteria and non-organic solvent to form a suspension containing cyanobacteria； (b) freezing the suspension with a temperature below 0°C to form a ice block and the ice block being melted at a low temperature, the whole step being repeated at least twice； (c) seperating the cyanobacterial residues and extract solution of the suspension； and (d)collecting the isolated cyanobacterial extract solution； wherein the cyanobacterial extract solution is a solution containing cyanobacterial bioactive substances. The pharmaceutical composition is able to effectively inhibit binding of sialic acid and hemagglutinin of influenza A and/or B virus, so as to inhibit infection and replication of influenza virus. Further, this pharmaceutical composition is able to inhibit infection of influenza virus resistant to neuraminidase inhibitors.
